Medical Director, Metroplex Clinical Research Center Metroplex Clinical Research Center UT Southwestern Medical School dallas, Texas
The first jak inhibitor for imid was approved in 2012 and now multiple jak inhibitors are available in the clinic. These oral small molecules have demonstrated significant efficacy for multiple indications similar or better than biologic dmards. Overall safety data reported from clinical trials and real-world data suggested similar adverse event risk to biologic dmards except for herpes zoster risk. In 2019 safety issues were reported in an fda mandated post approval study evaluating tofacitinib to tnf inhibitors in ra patients on background methotrexate. An increase in risk of mace, vte and malignancy was reported resulting in updated FDA and ema recommendations for use of jak inhibitors in imid. In this discussion we will review the evidence regarding jak inhibitor safety and how this will impact use in clinic of the approved therapies and therapies under investigation.
Learning Objectives:
Evaluation of adverse event profile of jak inhibitors in imid
Compare safety profile of jak inhibitors to biologic dmards
Evaluation of risk stratification for jak inhibitors in imid patients with comorbidities